Back to Search Start Over

DACH-LIGA Homocystein (German, Austrian and Swiss Homocysteine Society): Consensus Paper on the Rational Clinical Use of Homocysteine, Folic Acid and B-Vitamins in Cardiovascular and Thrombotic Diseases: Guidelines and Recommendations.

Authors :
Stanger, Olaf
Herrmann, Wolfgang
Pietrzik, Klaus
Fowler, Brian
Geisel, Jürgen
Dierkes, Jutta
Weger, Martin
Source :
Clinical Chemistry & Laboratory Medicine; Nov2003, Vol. 41 Issue 11, p1392-1403, 12p, 2 Diagrams, 4 Charts
Publication Year :
2003

Abstract

About half of all deaths are due to cardiovascular disease and its complications. The economic burden on society and the healthcare system from cardiovascular disability, complications, and treatments is huge and getting larger in the rapidly aging populations of developed countries. As conventional risk factors fail to account for part of the cases, homocysteine, a "new" risk factor, is being viewed with mounting interest. Homocysteine is a sulfur-containing intermediate product in the normal metabolism of methionine, an essential amino acid. Folic acid, vitamin B[sub12], and vitamin B[sub6] deficiencies and reduced enzyme activities inhibit the breakdown of homocysteine, thus increasing the intracellular homocysteine concentration. Numerous retrospective and prospective studies have consistently found an independent relationship between mild hyperhomocysteinemia and cardiovascular disease or all-cause mortality. Starting at a plasma homocysteine concentration of approximately 10 µmol/l, the risk increase follows a linear dose-response relationship with no specific threshold level. Hyperhomocysteinemia as an independent risk factor for cardiovascular disease is thought to be responsible for about 10% of total risk. Elevated plasma homocysteine levels (> 12 &micromol/l; moderate hyperhomocysteinemia) are considered cytotoxic and are found in 5 to 10% of the general population and in up to 40% of patients with vascular disease. Additional risk factors (smoking, arterial hypertension, diabetes, and hyperlipidemia) may additively or, by interacting with homocysteine, synergistically (and hence over-proportionally) increase overall risk. Hyperhomocysteinemia is associated with alterations in vascular morphology, loss of endothelial anti-thrombotic function, and induction of a procoagulant environment. Most known forms of damage or injury are due to homocysteine-mediated oxidative stress. Especially when acting as direct or indirect antagonists of cofactors... [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14346621
Volume :
41
Issue :
11
Database :
Complementary Index
Journal :
Clinical Chemistry & Laboratory Medicine
Publication Type :
Academic Journal
Accession number :
11519642
Full Text :
https://doi.org/10.1515/CCLM.2003.214